Temozolomide Comment.pdf (60.01 kB)
Download file

Going Past the Data for Temozolomide

Download (60.01 kB)
journal contribution
posted on 27.06.2012, 00:00 by J. Lee Villano, Nathalie Letarte, Linda R. Bressler
The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC‐NCIC CE.3) trial and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences on length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length than in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.

History

Publisher Statement

© 2012 by Springer Verlag, Cancer Chemotherapy and Pharmacology The original publication is available at www.springerlink.com DOI: 10.1007/s00280-011-1796-4

Publisher

Springer Verlag

Language

en_US

issn

0344-5704

Issue date

01/04/2012

Usage metrics

Categories

Exports